Neil William Aubuchon - 12 Jan 2026 Form 4 Insider Report for Viking Therapeutics, Inc. (VKTX)

Role
Chief Commercial Officer
Signature
/s/ Michael Morneau, as Attorney-in-Fact
Issuer symbol
VKTX
Transactions as of
12 Jan 2026
Net transactions value
$0
Form type
4
Filing time
26 Jan 2026, 19:57:19 UTC
Next filing
10 Mar 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Aubuchon Neil William Chief Commercial Officer 9920 PACIFIC HEIGHTS BLVD, SUITE 350, SAN DIEGO /s/ Michael Morneau, as Attorney-in-Fact 26 Jan 2026 0002106781

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction VKTX Stock Option (Right to Buy) Award $0 +180,000 $0.000000 180,000 12 Jan 2026 Common Stock 180,000 $31.76 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 25% of the shares subject to the option will vest immediately, and 25% of the shares subject to the option will vest on each one-year anniversary of the grant date over the next three years.